Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

Across the recent three months, 14 analysts have shared their insights on Gilead Sciences GILD, expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...

Gilead (GILD) Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s injectable HIV-1 capsid inhibitor ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir (LEN), a groundbreaking twice-yearly injectable HIV-1 capsid inhibitor ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year.

Hi, everyone. My name is Daina Graybosch. I'm a Senior Analyst here at Leerink Partners, covering largely immuno-oncology and also Gilead, which is broader than immuno-oncology. But today ...

FOSTER CITY, Calif., February 24, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated for parallel accelerated review the company’s ...

Last year, Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a single injection every six months.

In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed HIV with a single weekly oral dose, raising the hope of a new treatment option for patients.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer. The results of the TROPiCS ...